Geron Restructuring Sours Investors As Company Bets On Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.